PRL and acute lymphoblastic leukemia: The non-competitive small molecule PRL inhibitor, JMS-05340 significantly reduced the viability of T-ALL cells in a dose dependent manner (Fig. 6a), with lesser to no effects in cell lines that did not routinely express high levels of PRL-3.